This prospective, single-center, interventional study is conducted in order to achieve a biological bank accompanied by clinical data. Blood samples, optional tumor tissue and fecal samples are collected, processed and banked for all the included subjects. Those samples are collected before the start of treatment, at the time of first tumor assessment, at the time of first and second disease progression. The subjects are treated according to standard of care.

Clinical data are collected at each sampling time. The primary objective of the study is to identify biological, clinical and tumoral factors associated with tumor response according SOC treatment.

Inclusion Criteria:

• Documented new diagnosis of lung cancer by histology or cytology, or lung tumor leading to lung cancer suspicion without diagnosis for which an antineoplastic treatment is indicated
• Indication of a treatment by surgery, chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy as first line of lung cancer treatment
• ability of the subject to follow study procedures
• Age > 18 years
• Subject must have at least one measurable and/or assessable lesion in regard with RECIST 1.1 criteria
• Subject is registered with a social security scheme
• Subject is taken in charge at Pneumology department of Lille UH
• Subject has signed an informed consent form

Exclusion Criteria:

• Patient with a history of treatment by antineoplastic chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy, or presenting a contra indication to antineoplastic treatment administration
• Subject is not willing to sign the informed consent form
• Subject is not registered with a social security scheme
• Subject is not francophone
• Subject is deprived of his/her liberty or under trusteeship

This study includes patients taken in charge at UH Lille, department of pneumology and thoracic oncology (may be also treated at thoracic surgery department, in same hospital). The subjects have a lung cancer diagnosis (all stages are eligible) or a suspicion of lung cancer ; they are included before any treatment initiation.